Analysts Have Conflicting Sentiments on These Healthcare Companies: Vaxcyte (PCVX), Universal Health (UHS) and MoonLake Immunotherapeutics (MLTX)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vaxcyte (PCVX – Research Report), Universal Health (UHS – Research Report) and MoonLake Immunotherapeutics (MLTX – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Vaxcyte (PCVX)
BTIG analyst Thomas Shrader maintained a Buy rating on Vaxcyte today and set a price target of $89.00. The company’s shares closed last Friday at $61.74, close to its 52-week low of $58.10.
According to TipRanks.com, Shrader is a 4-star analyst with an average return of
Vaxcyte has an analyst consensus of Strong Buy, with a price target consensus of $105.14, representing a 77.6% upside. In a report issued on February 25, TipRanks – Google also upgraded the stock to Buy with a $69.00 price target.
See the top stocks recommended by analysts >>
Universal Health (UHS)
Wells Fargo analyst Stephen Baxter maintained a Hold rating on Universal Health yesterday and set a price target of $212.00. The company’s shares closed last Friday at $206.10.
According to TipRanks.com, Baxter is a 1-star analyst with an average return of
Currently, the analyst consensus on Universal Health is a Moderate Buy with an average price target of $251.00, representing a 23.0% upside. In a report issued on February 17, RBC Capital also maintained a Hold rating on the stock with a $245.00 price target.
MoonLake Immunotherapeutics (MLTX)
BTIG analyst Julian Harrison maintained a Buy rating on MoonLake Immunotherapeutics today and set a price target of $30.00. The company’s shares closed last Friday at $17.51.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for MoonLake Immunotherapeutics with a $25.83 average price target, a 47.7% upside from current levels. In a report issued on February 25, TipRanks – Google also upgraded the stock to Buy with a $20.00 price target.
